Brief: Theranexus FY Operating Income Down At EUR 25,000

Thx Pharma SA

25/04/2022 06:19

April 25 (Reuters) - Theranexus SA  ALTHX.PA :
    * THERANEXUS PUBLISHES ITS 2021 FULL-YEAR RESULTS AND
ANNOUNCES A
SHIFT OF ITS STRATEGIC FOCUS TO RARE NEUROLOGICAL DISEASES
    * DECISION TO DISCONTINUE THN102 FOR EXCESSIVE DAYTIME
SLEEPINESS
(EDS) IN PARKINSON'S DISEASE
    * DECIDED TO DISCONTINUE THN102 PROGRAM
    * GIVEN COMPANY'S RESOURCES, OTHER TWO THN PROGRAMS (THN101
AND
THN201), WHICH ARE IN AN EARLY CLINICAL PHASE AND INVOLVE BROAD
INDICATIONS THAT ARE HIGHLY CAPITAL-INTENSIVE, ARE ALSO BEING
DISCONTINUED
    * THIS DECISION WILL ENABLE COMPANY TO FOCUS ITS RESOURCES
ON ITS
DRUG CANDIDATE UNDER DEVELOPMENT FOR BATTEN DISEASE AND ITS
NEUROLEAD PLATFORM
    * WE HAVE DECIDED TO DISCONTINUE EQUITY FINANCING LINE PUT
IN
PLACE IN JANUARY 2022
    * AS OF 31 MARCH 2022, THERANEXUS REPORTED A CASH POSITION
OF EUR
13 M GIVING IT OVER 18 MONTHS' VISIBILITY
    * 2021 OPERATING INCOME EUR 25K VERSUS EUR 315K YEAR AGO
    * 2021 NET LOSS EUR 8,150K VERSUS LOSS EUR 4,797K YEAR AGO

Source text for Eikon:  urn:newsml:reuters.com:*:nACT74119
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))